The contemporary psychiatric, neuropharmacological, and public health landscape spanning the United States, United Kingdom, Germany, Japan, China, Canada, France, Netherlands, Switzerland, Australia, Dubai, Finland, and Austria is undergoing a historic transformation regarding the clinical re-evaluation of classical consciousness-altering agents. As academic investigators, clinical researchers, and public health authorities explore innovative therapeutic models for treatment-resistant psychiatric […]